5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Lasa Supergenerics Ltd.

•
lasalabs.comBSE: 540702NSE: LASA
Market Cap₹ 33 Cr.
Current Price
High / Low₹ 14 / 6
Stock P/E0.0
Book Value₹ 9
Price to Book1.14
Dividend Yield0.00 %
ROCE-13.2 %
ROE-20.2 %
Face Value₹ 10

Add ratio to table

ABOUT

KEY POINTS

Revenue Breakup Mar 2017 • Domestic Sales: 100.0%

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Working capital cycle has improved - days down from -10 to -38
  • Company generates healthy free cash flow
  • Company maintains a comfortable, low leverage position

CONS

  • Company is loss-making at the operating / net level
  • Company has a low return on equity of -17.2% over last 3 years
  • Company has a low return on capital employed of -13.5%
  • Interest coverage is weak at -8.6x - earnings barely cover interest
  • Poor cash conversion - profits are not backed by operating cash flow (CFO/PAT 0.09x)
  • Company's sales have been declining over the last five years

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTY 50NIFTY 500NIFTY LARGEMIDCAP 250NIFTY 100NIFTY 200
S.No.Name
1.SUNPHARMA1842.0036.54441957.500.872901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9326.0084.64247576.000.32902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4975.0086.76189233.010.76566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1119.5024.74111670.550.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1365.0032.72110272.680.95785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1970.3597.37106460.420.10362.07123.942026.3129.1018.2031.50
7.DRREDDY1161.0030.0796906.380.69435.60-69.108099.80-5.2113.7510.63
8.AUROPHARMA1675.4525.9796401.690.241032.0325.229150.3517.4412.7620.54
9.LUPIN2096.0017.3495842.920.861416.9816.018276.8934.2828.8629.59
10.MANKIND2277.0046.0494050.370.04574.0929.124030.5912.8913.2426.30
11.GLENMARK2416.9037.9468210.880.10482.83927.884018.4831.3520.3520.03
12.LASA6.590.0033.020.00-3.5883.051.23-93.87-13.23-113.45
Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
31242723313933392032-01
2723262729393336217324
Operating Profit411-42103-0-4-1-2-3
OPM %13.25%4.28%3.94%-17.44%5.84%2.03%0.79%8.71%-2.50%-130.72%-34.09%1630.77%-252.16%
000-9029-22-2000-01
Interest0101110000000
Depreciation3333333422212
Profit before Tax1-2-2-16-2-16-22-23-6-2-4-3
Tax %580.58%99.05%29.61%4.20%-46.77%-146.56%7.11%35.40%6.30%-10.04%-5.81%-4.77%-3.02%
Net Profit-5-0-1-15-3-35-14-21-6-3-4-4
-0.990.00-0.29-3.05-0.55-0.641.10-2.85-4.22-1.25-0.51-0.83-0.71

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024TTM
01992441701672021371301046
015320215913715512113610216
Operating Profit0464111304716-72-10
OPM %—22.91%16.94%6.52%17.92%23.33%11.68%-5.09%2.13%-156.74%
0-243100-8-18-90
Interest012118820420
Depreciation08181917161513116
Profit before Tax0215-16529-6-42-19-16
Tax %—-10.25%18.99%25.29%23.39%22.76%13.16%8.62%-13.70%-6.47%
Net Profit0212-12423-5-39-22-17
EPS0.00472.485.43-5.271.265.60-1.06-7.71-4.34—
Dividend Payout %—0.00%0.00%0.00%0.00%4.46%-23.49%0.00%0.00%—

COMPOUNDED SALES GROWTH

10 Years:
—
5 Years:
-9%
3 Years:
-20%

COMPOUNDED PROFIT GROWTH

10 Years:
—
5 Years:
—
3 Years:
—

STOCK PRICE CAGR

10 Years:
—
5 Years:
-38%
3 Years:
-39%
1 Year:
-49%

RETURN ON EQUITY

10 Years:
—
5 Years:
-7%
3 Years:
-17%
Last Year:
-20%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Corporate actions

2022

Sep 16

₹ 0.02

Rs.0.2500 per share(2.5%)Final Dividend

2021

Sep 15

₹ 0.02

Rs.0.2500 per share(2.5%)Final Dividend

Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Equity Capital0023234141505050
05594821011181086847
01049069340000
Trade Payables0254860341317914
04431221936343640
Total Liabilities0228287255229208209164151
0119170162152143137119110
Capital Work in Progress0297700553
03342322617111419
000000004
Cash & Bank0133641721
04565534443382414
Total Assets0228287255229208209164151

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
-0-34344144112-172
Cash from Investing00-44-7-2-4-311-0
Cash from Financing004-33-10-36-0-4-2
0-30-0216-10-0

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024

Shareholding Pattern

Numbers in percentages

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
53.6553.6553.6553.6553.6553.6553.6553.65
0.000.010.000.000.470.000.000.00
DIIs0.000.000.000.000.000.000.000.00
Government0.000.000.000.000.000.000.000.00
46.3546.3446.3546.3545.8846.3546.3546.35

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-09
General Updates

2026-09-09 - Lasa Supergenerics Limited has informed the Exchange about General Updates

2026-09-09
Outcome of Board Meeting

2026-09-09 - Lasa Supergenerics Limited has informed the Exchange regarding Outcome of Board Meeting held on September 09, 2026.

2026-09-02
Clarification - Financial Results

2026-09-02 - The Exchange has sought clarification from Lasa Supergenerics Limited for the quarter ended 30-Jun-2026 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: The response of the Company is awaited.

2026-08-26
Outcome of Board Meeting

2026-08-26 - Appointment of Mr Janardan Savala as additonal director in capacity of Executive Director

2026-08-25
Cessation

2026-08-25 - Lasa Supergenerics Limited has informed the Exchange regarding Cessation of Mr. ganesh as Executive Director of the company w.e.f. August 25, 2026.

2026-08-25
Resignation of Director/KMP/SMP

2026-08-25 - Lasa Supergenerics Limited has informed the Exchange about Resignation of Director/KMP/SMP

2026-08-14
Integrated Filing- Financial

2026-08-14 - Integrated filing for Quarter ended 30 june, 2026

2026-08-14
Outcome of Board Meeting

2026-08-14 - Lasa Supergenerics Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.

2026-07-18
Structural Digital Database

2026-07-18 - SDD certificate for the quarter ended June 2026

News

Recent coverage and analyst commentary for LASA

Loading news…

🤖

AI Stock Analyst

Lasa Supergenerics Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login